Introduction
The Jun oncogene was initially identified as the oncogenic effector of the avian sarcoma virus 17 (ASV17) (Maki et al., 1987) . The cellular homologue of the viral Jun (v-Jun) gene product, c-Jun, is the predominant component of the AP-1 family of se quence-specific transcriptional regulators. The Jun proteins display characteristics of bzip proteins, which include the presence of a leucine zipper region mediating dimerization and an adjacent basic region responsible for contacting DNA. Although Jun can form homodimers, its preference is to generate heterodimers with Fos family members. These complexes of Fos and Jun proteins bind and activate transcription through TPAresponsive elements (TRE) within gene promoters (Maki et al., 1987) . Distinct AP-1 dimers control specific gene targets and therefore regulate a diverse range of biological functions. These range from roles in cell growth and differentiation to stress signalling pathways (Vogt and Bos, 1990) .
The oncogenic v-Jun protein differs from c-Jun by two amino-acid substitutions in the C-terminal DNA binding domain and an N-terminal 27 amino-acid deletion (Maki et al., 1987) . These alterations are thought to cooperate to enhance the oncogenic potential of v-Jun. Although much is understood about how the alterations in v-Jun affect its contacts with DNA and modification by kinases, very little is known about the specific transcriptional targets of v-Jun and how these contribute to oncogenesis. Recently, several target genes upregulated by v-Jun have been identified. These include bkj (Hartl and Bister, 1995) , jtap-1 (Hadman et al., 1996) , HB-EGF (Fu et al., 1999) , TOJ3 (Bader et al., 2001) , RIL, CIS, and MKP2 (Fu et al., 2000) . In contrast, c-Jun (Kilbey et al., 1996) , SPARC, SSeCKS, and apolipoprotein A-1 are all downregulated by v-Jun (Vogt, 2001) . One of the key characteristics of the v-Jun oncogene is its transforming potential in chick embryo fibroblasts (CEFs) and to date, of the target genes identified only HB-EGF and TOJ3 have been demonstrated to induce alterations in growth control, although HB-EGF expression alone did not demonstrate the full repertoire of the transformed phenotype evident following v-Jun expression.
v-Jun has opposing functions on transcription; on some promoters it is less active than c-Jun, whereas on others it has a stronger transactivation potential than cJun (Gao et al., 1996; Kilbey et al., 1996) . In this context, it is important to study genes that are both up and downregulated by v-Jun as it seems highly likely that it will be a combination of these changes in gene expression that contribute to the oncogenic potential of this protein.
The proliferation of mammalian cells is controlled by the balance between growth inducing and growth inhibitory signals that converge through distinct signalling networks on the cell cycle machinery. This regulatory machinery is composed of cyclins, cyclindependent kinases (CDKs), and their inhibitors, cyclindependent kinase inhibitors (CKIs). These proteins act in concert to control cell cycle progression at specific regulatory stages of the cell cycle by directing the cell towards a response of proliferation, growth arrest, or apoptosis (Hartwell and Kastan, 1994) . The CKI can be classified into two groups that differ in both sequence homology and their targets of inhibition, the Ink4 and CIP/KIP families (LaBaer et al., 1997) . All the CIP/KIP family proteins contain discrete cyclin and cdk binding domains near the N-terminus and the interaction of these proteins with cyclin/cdk complexes is sufficient to enforce cell cycle arrest throughout the G1/S phase of the cell cycle. Of the known CIP/KIP family proteins, p21 CIP1 is the only CKI whose promoter is activated by the tumour-suppressor protein p53 (el-Deiry et al., 1993) . The p21 CIP1 gene promoter is activated by a wide range of stimuli and is involved in the mediation of a number of different growth arrest signals via both p53-dependent and p53-independent mechanisms (Gartel and Tyner, 1999) . It is induced in response to DNA damage via p53, during terminal differentiation and following TGFb stimulation, both of which are p53-independent pathways. p21 CIP1 expression can also be stimulated by serum growth factors during cell cycle reentry, demonstrating that the actions of p21 CIP1 are not limited to cell cycle arrest and that it plays a more dynamic role in the control of cell growth than previously appreciated.
Recent studies in c-Jun knockout mice have revealed that c-Jun is required for normal cell proliferation. Primary mouse embryo fibroblasts derived from c-Jundeficient cells were observed to growth arrest after a short time in culture (Schreiber et al., 1999) and this growth arrest phenotype was shown to be dependent on p53. Biochemical studies on c-Jun-deficient 3T3 cell lines have suggested a role for c-Jun in negatively regulating p21 CIP1 expression indirectly by inhibiting p53 gene transcription (Schreiber et al., 1999) , or alternatively, by negatively regulating the association of p53 with the p21 CIP1 gene promoter (Shaulian et al., 2000) . In this latter study, cells lacking c-Jun were demonstrated to have prolonged p21 CIP1 induction resulting in a p53-dependent growth arrest after UV irradiation (Shaulian et al., 2000) . In many instances c-Jun and vJun are thought to target the same genes and given the positive effect that both proteins have on cell proliferation we reasoned that v-Jun might also affect p21 CIP1 expression or function. Here we document repression of p21 CIP1 during cell transformation by v-Jun and suggest that this repression is mediated by both p53-dependent and p53-independent mechanisms.
Results

Isolation and characterization of the chick homologue of p21 CIP1
Previous studies have shown that v-Jun-transformed CEFs display accelerated G1/S progression, which is associated with a large increase in cyclin E/cdk2 kinase activity . Although the cause of this increase was not established, no corresponding elevation in the level of the putative rate-limiting cyclin E component of the cyclin E/cdk2 kinase complex was observed . Cdk2 kinase activity is however also subject to stringent negative regulation mediated by the CIP/KIP families of cdk inhibitor proteins, raising the possibility that a decrease in the level of one or more inhibitor molecules might contribute to cdk2 deregulation. The levels of p27 KIP1 mRNA and protein were not greatly altered as a result of cell transformation by v-Jun (Clark et al., 2000, unpublished results) ; however, we were unable to evaluate the possible involvement of p21 CIP1, since the avian homologue of this inhibitor had not been described and no available antibodies detected the avian p21 CIP1 protein.
To allow investigation of the possible involvement of p21 CIP1 in cell cycle deregulation by v-Jun, a chick p21 CIP1 cDNA was isolated from a lZAPII cDNA library constructed from chick E7 retina mRNA. The sequence of this cDNA together with its predicted translation product is shown in Figure 1a . The cDNA is 1562 nucleotides long and contains a putative initiator ATG codon at nucleotide 48 and an in-frame termination codon at nucleotide 472, predicting a translation product of 17.8 kDa. Comparison of the chick p21 CIP1 amino-acid sequence with homologues from other vertebrate species revealed that the functional domains involved in cyclin, cdk, and PCNA binding were well conserved (Figure 1b) , but that the intervening regions were much less so.
p21 CIP1 mRNA and protein expression is downregulated in v-Jun-transformed cells
To determine the role of p21 CIP1 in cell cycle deregulation by v-Jun, we first compared p21 CIP1 expression in control and v-Jun-transformed cells. p21 CIP1 mRNA levels were substantially reduced in exponentially growing (growth medium, GM) v-Jun CEF when compared to control CEFs (Figure 2a ). Under conditions of serum growth factor deprivation (low serum, LS) control CEF exit the cell cycle and enter a state of growth inhibition until further mitogenic signals are encountered. This cell cycle exit was associated with a large increase in p21 CIP1 mRNA (Figure 2a ). In comparison, no corresponding increase in p21 CIP1 was observed in v-Jun CEF, which continue to cycle in the absence of serum mitogens (Clark and Gillespie, 1997) . p21 CIP1 has been documented to be regulated both transcriptionally and by mechanisms that involve protein stability (Haapajarvi et al., 1999) . To analyse v-Jun represses p21 CIP1 gene expression A MacLaren et al p21 CIP1 protein expression in CEF, an avian-specific polyclonal antiserum was generated by immunizing rabbits with a bacterially expressed GST-cleaved fulllength avian p21 CIP1 protein. Figure 2a (lower panel)
demonstrates that p21 CIP1 protein expression was also reduced in v-Jun CEF compared to controls and failed to increase following serum mitogen deprivation. These results demonstrate that p21 CIP1 mRNA and protein An additional signal known to induce a p21 CIP1-dependent growth arrest occurs when cells reach high densities and contact inhibition occurs (Macleod et al., 1995; Gartel and Tyner, 1999; Erhardt and Pittman, 1998) . To determine whether p21 CIP1 protein levels also increased when untransformed cells reached confluency, CEF were harvested 24 h following plating when cells were approximately 20-30% confluent (sparse) or 96 h following plating when cells were 100% confluent (confluent). p21 CIP1 protein levels increased at high densities in control CEF but not in v-Jun-transformed CEF, which do not respond to contact inhibition (Figure 2b) (Vogt, 2001) .
In normal untransformed cells, p21 CIP1 increases are associated with the ability to quiesce following serum deprivation and contact inhibition at high densities. The failure to induce p21 CIP1 in v-Jun CEF may contribute to the inability of these cells to exit the cell cycle following either serum withdrawal or contact inhibition. Our results show a correlation between deficiencies in p21 CIP1 expression in v-Jun-transformed cells and aberrant growth control and imply that p21 CIP1 deregulation may result in some of the defining features we associate with the transformed cell.
Ectopic expression of p21 CIP1 inhibits accelerated cell cycle progression and elevated cdk2 kinase activity in v-Jun-transformed CEF To evaluate the functional significance of p21 CIP1 downregulation, we first determined the effect of ectopic p21 CIP1 expression on DNA synthesis in control and v-Jun-transformed cells. Expression plasmids encoding chicken p21 CIP1 or empty vector were microinjected together with a GFP injection marker into both cell types. After allowing time for transgene expression, the percentage of cells that synthesized DNA was determined by BrdU labelling. v-Jun-transformed CEF injected with control plasmid exhibit a much higher labelling index than normal CEF (65 vs 19%) under these conditions owing to more rapid G1/S progression (Clark and Gillespie, 1997) ; however, ectopic expression of p21 CIP1 resulted in an almost complete block in DNA synthesis in both cell types (Figure 3a) . These results suggest that the level of p21 CIP1 is an important determinant of G1/S regulation in both normal and v-Jun-transformed CEF.
As an alternative approach to this question, we sought to overexpress human p21 CIP1 together with v-Jun using a dual-retroviral infection approach. v-Jun was expressed using a replication competent vector, RCAS(A)-v-Jun, in combination with an RCAS(B)-human p21 virus. This strategy has been shown to achieve stable and uniform expression of two transgenes in doubly infected CEF cultures ; however, in this case high levels of exogenous p21 expression were obtained only transiently. Western blotting analysis revealed that human p21 CIP1 expression was maximal at passage three (during initial virus spread) but then rapidly declined, presumably because cells expressing high levels of human p21 CIP1 were growth arrested and progressively lost from the cultures (Figure 3b ). Although this outcome precluded subse- , or after 48 h in low serum-containing medium (LS), were analysed for p21 CIP1 and GAPDH mRNA expression (upper panels). Whole-cell extracts were prepared from sister cultures and p21 CIP1 protein expression analysed by Western blotting using a polyclonal antisera, which recognized either chick p21 CIP1 or Erk (lower panels). (b) Cultures of control or v-Jun-transformed CEF growing in normal growth media were harvested either 24 h after plating (sparse) or after culture for a further 72 h after which time control cells had reached confluence. Whole-cell extracts were prepared and analysed by SDS-PAGE for p21 CIP1 and Erk expression v-Jun represses p21 CIP1 gene expression A MacLaren et al quent analysis of the effects of ectopic p21 CIP1 expression on cell proliferation or cdk2 kinase activity, this result provided further evidence that excess p21 CIP1 expression was strongly growth inhibitory in v-Jun-transformed CEF.
In an attempt to circumvent this obstacle, we fused human p21 CIP1 to the hormone-binding domain of the mouse estrogen receptor (ER) to generate a chimeric p21ER protein, which we hoped would exhibit tamoxifen-dependent function (Blalock et al., 2000) . In an additional modification, p21ER was expressed from the neomycin selectable SFCV retroviral vector using RCAS v-Jun to provide helper virus function. Since we anticipated that the chimeric p21ER protein would be active only in the presence of tamoxifen, doubly infected cell cultures were prepared in the absence of hormone. Following tamoxifen treatment, p21 CIP1 expression could be detected in the doubly infected cell cultures and was observed to be stable throughout the duration of the experiments (Figure 4a and data not shown). Unexpectedly however, we also observed that p21 CIP1 expression was readily detected at similar levels in the absence of hormone (Figure 4a ). Furthermore, the ectopically expressed p21CIP1 we detected was not fused to the ER ligand-binding domain, apparently because of cleavage of the chimeric p21ER protein. The cleaved human p21 CIP1 protein present in the cells could be detected with antibodies directed against either the N-or C-terminus (data not shown). For unknown reasons, we were not able to detect an intact chimeric p21ER fusion protein.
Analysis of the growth rates of these cell cultures in the presence of hormone revealed that ectopic expression of human p21 CIP1 attenuated the proliferation of the v-Jun-transformed CEF such that their growth rate was reduced to levels comparable to SFCV vector controls ( Figure 4a ). This was because of a slowing in the rate of G1/S progression as judged by a reduction in the proportion of cells in S phase as measured by BrdU labelling and flow cytometry ( Figure 4b ). These results demonstrate that exogenous expression of human p21 CIP1 reduces the accelerated growth capacity of v-Juntransformed cells, implying that the reduction in endogenous p21 CIP1 expression could contribute to this growth deregulation. p21 CIP1 inhibits cell cycle progression at least in part by inhibiting cdk2, therefore we also investigated whether exogenous p21 CIP1 expression attenuated the elevated level of cdk2 kinase activity observed in vJun CEFs. Total cdk2 activity was approximately threefold higher in v-Jun-transformed CEF in this experiment; however, expression of p21ER in combination with v-Jun reduced cdk2 kinase activity to a level two-threefold lower than that observed in control cells (Figure 4c ). Thus, ectopic expression of p21 CIP1 not only reverses the more rapid cell cycle progression induced by v-Jun, but also inhibits a biochemical activity that is closely associated with this phenotype.
Analysis of functional elements within the p21 CIP1 promoter that mediate repression by v-Jun
To investigate the mechanism through which v-Jun disturbs p21 CIP1 mRNA expression, we examined the activity of the human p21 CIP1 promoter in v-Juntransformed cells. As shown in Figure 5a , the full-length construct (p21p), which contains 2.5 kB of the promoter and includes both p53 response elements (p53RE), was substantially less active in v-Jun CEF compared to control CEFs. To determine which region of the promoter was mediating this repression, we transfected a series of progressive 5 0 promoter deletion mutants of the human p21 CIP1 promoter into control and v-Juntransformed CEF. The p21pD1.9 construct, which contains 600 bp proximal to the transcriptional initiation site but has lost both p53RE, showed a similar pattern of activity to the full-length reporter, although the absolute level of activity was much lower, suggesting were generated and cells harvested for protein analysis at passages 3 (p3), p4, or p5, which represent 3 day intervals between passaging. Whole-cell extracts were prepared, quantitated, and Western blotting was performed. Human-specific p21 antisera used to detect the exogenous human p21 CIP1 protein. Equal loading was confirmed by Ponceau S staining of the membrane v-Jun represses p21 CIP1 gene expression A MacLaren et al that p53 binding accounts for a large component of the activity of the p21 CIP1 promoter. In fact, this trend of reduced activity in v-Jun CEF was evident with all of the deletion constructs tested showing an approximate 15-fold reduction in activity in transformed cells compared to control (Figure 5a ). In contrast, a control construct (pFosLuc) containing a minimal fragment of the murine c-Fos promoter was expressed equally well in both cell types indicating that v-Jun does not impair global gene transcription. Strikingly, the p21pSmaD1 construct, which contains only around 60 bp proximal to the transcription initiation site (À61 bp to +16 bp), was also much less active in v-Jun CEF implying that if a specific element was responsible for this attenuation it had to reside within this region of the promoter.
To further investigate the basis for the differential activity of the p21 promoter, a series of point mutant promoter constructs were used. Six mutant promoter constructs, each of which contained 10 consecutive mutated bases within specific functional elements were analysed (Datto et al., 1995) . These mutants were generated from the p21p93-S construct and spanned the region from À93 to -34 ( Figure 5b ). All of these mutant constructs showed reduced activity in the v-Jun CEF background. No individual mutation reduced the activity observed in control cells to a level comparable to that observed in transformed cells. From these studies, we concluded that v-Jun repression of the p21 CIP1 promoter could not be attributed to a deficit in the activity of a single functional element in this minimal region of the p21 promoter. The p21 CIP1 protein was initially identified as a DNA damage inducible protein that could be directly transcriptionally induced by the tumour-suppressor p53 (elDeiry et al., 1993) . Evidence from studies on cells either deficient or mutant for p53 has revealed that loss of p53 function results in a dramatic reduction in the levels of p21 CIP1 mRNA (Macleod et al., 1995) . For these reasons, we decided to determine whether the reduction in p21 CIP1 in v-Jun CEF was because of a deficiency in p53 expression or activity. Northern analysis demonstrated that there was no significant decrease in the basal levels of p53 mRNA in v-Jun CEF (Figure 6a, top panel) . Unlike p21, most of the regulation of p53 occurs post-translationally; therefore, we decided to examine the level of the p53 protein.
Relative to control CEFs, v-Jun-transformed cells did not appear to have any substantial reduction in the basal levels of p53 that could account for the observed decline in p21 CIP1 expression (Figure 6a, lower panel) .
Under normal circumstances the p53 protein has a very short half-life. Following damage to DNA, wildtype p53 protein accumulates rapidly via a posttranscriptional stabilization mechanism that involves inhibition of ubiquitin-dependent degradation (Cox, 1997) . We examined the effect of a range of protease inhibitors on p53 expression to determine whether v-Jun interfered with the regulation of p53 stability. Treatment of the cells with an inhibitor of the ubiquitin-dependent 26S proteasome, MG132 (Rock et al., 1994) , and a range of other protease inhibitors, some of which partially inhibit the 26S proteasome, resulted in an increase in the basal levels of p53 in both cell types. No difference was evident in the absolute levels of p53 that accumulated in each cell type when degradation was blocked, implying that there was no major difference in the stability of p53 in the presence of v-Jun (Figure 6b) .
These results demonstrated that p53 mRNA and protein expression was not obviously deficient in v-Jun CEF, but did not address conclusively whether the p53 protein was fully functional. To investigate p53 transcriptional activity in v-Jun-transformed cells, we utilized the p53-responsive Mdm2 proximal gene pro- Mutant constructs #1-6 were identical to p21 CIP1p93-S except that a 10 bp sequence was mutated in each construct and have been described elsewhere (Datto et al., 1995) . Luciferase activity was measured 48 h following transfection and results shown are the mean of three experiments7s.e.m v-Jun represses p21 CIP1 gene expression A MacLaren et al moter as a read-out of p53 function. Activation of the Mdm2 gene by p53 involves the direct interaction of p53 with two response elements located within the first intron of the gene (Juven et al., 1993) . Remarkably, this p53-responsive Mdm2-CAT reporter construct was also significantly less active in v-Jun CEF compared to controls (Figure 7a ).
Since the Mdm2 gene promoter is primarily dependent on p53, this suggested that p53 transcriptional activity might be attenuated in v-Jun CEF. To address this further, we generated point mutations within the two p53 consensus binding elements in the Mdm2 reporter. These mutations were designed to abolish p53 binding and thus render the promoter non-p53 responsive (Figure 7a , upper). Mutation of these p53REs resulted in the loss of the majority of activity from this reporter, when compared to the wild-type Mdm2 promoter fragment.
To determine whether defects in p53 DNA binding activity were the cause of the repression observed on the p21 and Mdm2 promoters, we generated a concatamerized miminal p53-responsive Mdm2 promoter oligonucleotide and captured this DNA on magnetic beads. Following exposure to UV to activate p53, cell extracts were incubated with these oligo-coated beads and we examined the quantities of p53 captured in both cell backgrounds (Figure 7b ). These studies revealed that a similar amount of p53 was captured from both cell extracts with wild-type p53REs (lanes 5 and 7), implying that v-Jun expression does not affect the DNA binding potential of p53. These results suggest that the alterations in p53 function in v-Jun-transformed cells are more complex than inhibition of p53 DNA binding.
A recent study has reported that this Mdm2 promoter under some circumstances may be regulated by AP-1 (Ries et al., 2000) , and a consensus TRE binding element has been observed approximately 25 bp upstream of the p53 REs. To determine whether the repression we observed in this Mdm2 promoter fragment was due to v-Jun-repressing transcription through a TRE site, we generated point mutations in this site in both the wild-type and mutant p53RE backgrounds and assayed the transcriptional activity of these reporters. These results demonstrated that mutation of the TRE site alone reduced the overall transcriptional activity of the promoter by approximately 25% (Figure 7c ). Despite this overall reduction, mutation of this TRE site did not relieve repression in v-Jun CEF. Our previous experiment (Figure 7a ) had demonstrated that almost all of the transcriptional activity of this promoter is lost when the p53 binding sites were abolished. These results suggest that the activity of the wild-type Mdm2 construct observed in control cells was dependent on these two p53REs and imply that the reduced activity of the wild-type Mdm2 promoter observed in v-Jun CEF may be because of a defect in p53 function. Although these observations are suggestive of defects in p53 function, they did not directly address whether these defects were because of deficiencies in p53's transactivation activities.
To determine whether p53 transcriptional activation function was diminished in v-Jun-transformed cells, we utilized a Gal4-activated promoter system consisting of the p21 CIP1 core promoter fused downstream of 5 Gal4-DNA binding sites (Gregory and Perkins, manuscript in preparation). This chimeric promoter was transfected with activated plasmids encoding Gal4 fused to the p53 activation domain (amino acids 1-42), Gal4 alone, or Gal4-VP16 as controls. We observed that Gal4-p53 activity was similar in both cell backgrounds using this p21 CIP1 core promoter (Figure 7d ). Similar results were observed when the core promoter from the p53-responsive Bax gene was substituted for p21 CIP1. These results show that the ability of the chimeric p53 activation domain to drive gene transcription was not impaired in v-Jun-transformed cells and suggest that p53-dependent gene transcription is antagonized by v-Jun in a manner that is independent of both the transactivation function and DNA binding potential of p53.
Discussion
Previously we demonstrated that v-Jun promotes cell cycle progression and S-phase entry at least in part by stimulating cyclin E/cdk2 kinase activity (Clark et al., Figure 6 v-Jun does not modulate p53 expression. (a) CEF and vJun CEF were cultured under growing conditions for 48 h and either nuclear extracts or polyA + RNA were prepared from duplicate plates. Northern blotting was performed using an avian p53 cDNA and full-length GAPDH cDNA (upper panels). Western blotting was performed to analyse p53 or Erk expression in nuclear extracts (lower panels). (b) Growing CEF and v-Jun CEF were treated with 100 mm of various protease inhibitors for 3 h. Nuclear extracts were prepared and Western blotting analysis was done using an anti-p53 monoclonal antibody, and a nonspecific band (NS) was shown to confirm equal loading v-Jun represses p21 CIP1 gene expression A MacLaren et al
2000)
. In these studies, we did not observe any increase in the level of the putative rate-limiting subunit of this complex, cyclin E, which could account for the increased kinase activity, leading us to postulate that a decrease in the expression or activity of a cdk2 inhibitor molecule might be involved. Cdk2 kinase activity is subject to a negative regulation by the p27 KIP1 and p21 CIP1 proteins; however, the level of p27 KIP1 protein and mRNA expression was not grossly altered in v-Juntransformed CEF (Clark et al., 2000, unpublished results) . Recently, studies using c-Jun-deficient MEFs have led to the suggestion that p21 CIP1 expression can be regulated by c-Jun (Schreiber et al., 1999) , prompting us to investigate whether alterations in p21 CIP1 expression might contribute to cell cycle deregulation by v-Jun. To accomplish this, it was necessary to first isolate and characterize the avian homologue of p21 CIP1, Figure 7 v-Jun attenuates p53 transcriptional activity. (a) The two Mdm2 p53 response elements were aligned with a consensus p53 binding site. Positions 4 and 7 of each half 10 bp site were mutated to A and T, respectively, to render the construct nonresponsive to p53 (upper panel). The exception to this was position 4 in the first half site in the second p53RE, which has a T rather than the consensus C at this position therefore this base was not mutated. Wild-type and p53-mutated Mdm2 promoter constructs were transfected into CEF and v-Jun CEF and CAT activity measured 48 h later. Results shown are the mean of three experiments7s.e.m (lower panel). (b) Extracts from CEF or v-Jun CEF were incubated with either collagenase TRE, wild-type Mdm2, or mutant p53 site Mdm2-coated beads. Captured proteins were eluted and analysed by Western blotting for p53 or Jun expression. (c) The TRE site 25 bp upstream of the first p53RE in the Mdm2 promoter was mutated either alone, or in the presence of p53 mutations, from TGACTCA to GGACGCA. Wild-type and mutated promoter constructs were transfected into CEF and v-Jun CEF, and CAT activity was measured 48 h later. Results shown are the mean of three experiments7s.e.m (lower panel). (d) Constructs containing the core promoter of p21 (p21 CIP1-Luc) or Bax (Bax-Luc) were transfected alone or in combination with Gal4p53AD or Gal4-VP16 were transfected into CEF and v-Jun CEF and luciferase activity measured 48 h later. The results shown are the mean of three experiments7s.e.m v-Jun represses p21 CIP1 gene expression A MacLaren et al since this had not previously been described. As we have shown, chick p21 CIP1 exhibits striking similarity to the corresponding mammalian homologues in the regions known to be required for binding to cyclins, cdks, and PCNA. Although the intervening regions are more divergent, the high degree of conservation of these important functional domains suggests that avian p21 CIP1 is likely to function in an analogous manner to its mammalian counterparts.
Subsequent investigation revealed that p21 CIP1 mRNA and protein were dramatically repressed in growing v-Jun CEF compared to untransformed cells, consistent with the more rapid rate of G1/S progression and increased cdk2 kinase activity. Furthermore, in control CEF p21 CIP1 expression increased during quiescence induced by either serum deprivation or confluency (Macleod et al., 1995) , however these increases failed to occur in v-Jun-transformed cells. In contrast, p27 KIP1 levels increased to a similar degree in both cell types following these treatments (data not shown) implying that in avian fibroblasts p21 CIP1 is the major cdk inhibitor regulating cell cycle exit. This inability to upregulate p21 CIP1 expression in response to negative growth signals could contribute to the failure of v-Jun CEFs to exit the cell cycle following serum mitogen withdrawal and the failure to growth arrest at high densities, two defining characteristics of transformed cells.
To test the functional significance of the decrease in p21 CIP1 expression directly, we expressed exogenous p21 CIP1 in v-Jun CEF by microinjection and retroviral gene transduction. This allowed us to demonstrate that acute ectopic expression of avian p21 CIP1 blocked DNA synthesis in v-Jun-transformed CEF completely, while stable retroviral coexpression of human p21 CIP1 together with v-Jun slowed the rate of cell cycle progression and reduced the level of cdk2 kinase in the doubly transduced cultures to a level below control cells. Taken together, these observations indicate that repression of endogenous p21 CIP1 expression is indeed likely to contribute to cell cycle deregulation by v-Jun in CEF. The ability of the v-Jun-transformed cells to proliferate at a rate similar to control CEF despite the negligible cdk2 kinase activity observed suggests that v-Jun, in addition to repressing p21 CIP1, also utilizes another mechanism(s) to drive proliferation.
We also investigated the mechanism through which vJun disturbs p21 CIP1 expression, and in particular whether v-Jun might act indirectly via p53. Transfection studies revealed that p21 CIP1 promoter constructs were much less active in v-Jun-transformed CEF compared to control, suggesting that most, and perhaps all, of the decrease in p21 CIP1 mRNA is likely to be mediated at the level of gene transcription. The differential activity of these constructs did not however depend on the presence of the characterized upstream p53-responsive elements in the p21 CIP1 gene promoter, nor did we see any attenuation of p53 mRNA or protein expression in v-Jun-transformed CEF compared to control. In fact, repression was also observed with a minimal p21 CIP1 promoter fragment (-61 to +16 bp) that is not known to be p53-responsive, although it was not possible to assign this effect to any other single functional element identified within this region. Transient expression of vJun was shown not to be sufficient for p21 repression (data not shown) suggesting that the effect of v-Jun on the p21 gene promoter may be indirect.
Although these observations indicated that p21 CIP1 repression in v-Jun-transformed cells could not be mediated solely through p53, they did not completely exclude a contribution from a p53-dependent mechanism. Firstly, the truncated p21 CIP1 reporters which lack the upstream p53-responsive elements are only weakly active compared to wild type (see Figure 5a ; 15-fold reduction in activity of p21pD1.9 compared to p21p), suggesting that the major regulator of p21 CIP1 expression in these cells is p53. Secondly, p53 function can be regulated by post-translational mechanisms, which cannot be monitored at the level of protein expression. We therefore used the Mdm2 gene promoter, whose transcriptional activity is almost exclusively reliant on p53 (Juven et al., 1993) , as an independent measure of p53 function. Remarkably, the Mdm2 promoter was also significantly less active in v-Juntransformed CEF than controls. We believe that this is attributable to a specific reduction in p53 transcriptional activity, since the activity of the Mdm2 promoter is almost entirely dependent on the p53-responsive elements in both cell backgrounds. Mutation of a TRE site present in the Mdm2 promoter ruled out the possibility that v-Jun was repressing Mdm2 through this specific site rather than through the p53REs. Further evidence for v-Jun CEF exhibiting defects in p53 function come from microarray analysis, which has shown that two additional endogenous p53-responsive genes, cyclin G1 and ribonucleotide reductase, are also repressed as a result of cell transformation by v-Jun (Black et al, manuscript submitted). Studies using a Gal-fused p53 transactivation domain demonstrated that although vJun antagonizes p53 transcriptional activity it does not mediate this effect by inhibiting the transactivation function of p53, nor does it compromise the DNA binding activity of p53. Taken together, these observations indicate that the repression of p21 CIP1 as a result of cell transformation by v-Jun is likely to be attributable to both p53-dependent and -independent mechanisms.
Studies with c-Jun knockout mice have recently implied a role for c-Jun as a regulator of p53 function. Schreiber et al. (1999) demonstrated that c-Jun-deficient MEFs arrest prematurely in culture and have shown that this proliferation block was caused by an increase in the expression of p53 and p21. They suggest that c-Jun functions as a negative regulator of p53 gene transcription and in support of this overexpression of c-Jun was observed to repress both p53 and p21 expression. More recently, Shaulian et al. (2000) presented data demonstrating that c-Jun negatively regulates p53 association with the p21 CIP1 promoter. The results from these studies are strikingly similar to those we observed with v-Jun, although two major differences exist. Deletion of the two known p53REs from the p21 CIP1 v-Jun represses p21 CIP1 gene expression A MacLaren et al gene promoter revealed that these binding elements were not the sole cause of v-Jun-mediated repression of this gene. Schreiber et al. (1999) report that c-Jun mediates its effects at the level of p53 gene transcription. We, in contrast, did not observe any defects in p53 expression although we did document deficiencies in p53 function in v-Jun-transformed cells. In addition to the above evidence for c-Jun acting to repress p21 indirectly via p53, there is also evidence for c-Jun acting in a p53-independent manner, either directly or in synergy with other transcription factors on the p21 CIP1 promoter (Kardassis et al., 1999; Chen and Chang, 2000) . In contrast, other reports have demonstrated that c-Jun can repress p21 CIP1 (Tsao et al., 1996; Wang et al., 2000) . One specific Sp1 site between -77 to -83 bp has been demonstrated to mediate this repression. In the study described here, we mutated this particular Sp1 site (p21 p93-S mut#2 construct in Figure 5b ) and although there was less activity with this construct it did not abolish the differential activity observed between the two cell types, implying that v-Jun does not appear to function in an analogous manner to c-Jun in 293 cells (Wang et al., 2000) .
The reduction in p21 CIP1 levels in v-Jun-transformed cells could be postulated to have a number of functional consequences on the cell. One of the characteristics of these transformed cells is the loss of anchorage-dependence and the ability to grow independently of cell-matrix interactions. The p53-p21 CIP1 pathway has been suggested to play a role in the control of proliferation following the disruption of cell-matrix interactions (Wu and Schonthal, 1997) and the loss of p21 CIP1 induction in v-Jun-transformed cells may in part account for the ability of this oncogene to sustain anchorage-independent growth. Additionally, failure to express sufficient levels of p21 CIP1 has been observed to convert a normal cell cycle arrest response into one of apoptotic cell death (Gervais et al., 1998) , which correlates with the observations that overexpression of v-Jun has been demonstrated to sensitize cells to apoptosis .
If downregulation of p21 CIP1 plays a significant role in permitting v-Jun to bypass negative growth control and is functionally significant to the transformed cell phenotype, then it would be predicted that other oncogenes may also utilize this mechanism. This has indeed been shown to be the case for the c-Myc oncogene. Myc has been documented to inhibit p21 CIP1 expression in a number of cell lines (Mitchell and El-Deiry, 1999; Claassen and Hann, 2000; Coller et al., 2000; Gartel et al., 2001) . These studies display striking similarities to those we report for v-Jun and suggest that the repression of p21 CIP1 by oncogenes may therefore be a more generic mechanism with which to subvert growth arrest.
Very few cancers have been documented to have a loss or mutation in p21 CIP1 (Hall and Peters, 1996) , but many tumours have lost p53 function thereby being unable to respond to damaging events. In tumour cells with wild-type p53, the loss of p21 CIP1 expression by homologous recombination results in cell death through apoptosis (Waldman et al., 1996) . It may be possible in the tumour cell that by blocking one arm of the downstream p53 response to DNA damage, the balance can be altered to favour cell killing. In this context, it will be of interest to examine in detail how these oncogenes achieve repression of the p21 CIP1 gene promoter as this may lead to a better understanding of how to modulate p21 CIP1 expression in the tumour and sensitize cells to apoptosis following genotoxic damage.
Materials and methods
Cell culture and retroviral vectors
Cultures of primary CEFs were grown in DMEM supplemented with 10% newborn calf serum, 1% heat-inactivated chick serum (GM), or in LS conditions containing 0.2% newborn calf serum only. Medium was replaced on growing cultures every 48 h. To block protease function in the cells, CEF were treated for 3 h with 100 mm calpain inhibitor I, 100 mm calpain inhibitor II, and 100 mm MG132 (all obtained from Sigma).
For retroviral infections, primary CEFs were transfected with the appropriate DNA or combinations of DNA and the cultures passaged until uniform infection was accomplished. The replication-defective ASV17 (v-Jun retrovirus) was regenerated using the RCAS virus, which is a subgroup A replication competent virus, as helper. RCAS(B) human p21 has been described elsewhere (Givol et al., 1995) . Human p21 estrogen receptor (ER) constructs were generated by fusing a HindIII/ClaI (end-filled) p21 CIP1 fragment to a BamHI(endfilled)/ClaI murine ER fragment in pKS -. The resultant p21 ER HindIII/ClaI fragment was subsequently cloned into the neomycin selectable vector, SFCV. SFCV or SFCV-p21 ER virus was replicated using RCAS or RCAS v-Jun as helper. At 3 days after infection, cultures were selected with G418 and pools of infected cells were generated.
Chick p21 isolation and sequencing
A cDNA corresponding to avian p21 CIP1 was isolated from a chick E7 retinal cDNA library. Once excised into pKS À the avian p21 CIP1 cDNA clone was sequenced in both directions and overlapping sequences generated. The final sequence was compiled using a GCG package and compared to the other p21 homologues using the Clustalw alignment tool. The sequence has been submitted to GenBank (Accession number AF 513031).
Microinjection
Cells were microinjected using a Zeiss Axiovet 100 microscope as described previously . pCDNA3.1-avian p21 CIP1 was generated by cloning a 1.3 kB EcoRI/XhoI fragment from the library generated pKS -avian p21 CIP1 into pCDN3.1. This cDNA lacks the last 300 bp of the 3 0 untranslated region. At 24 h after injection, the cells were incubated in a medium containing 25 mm BrdU. Injected cells were fixed following a further 24 h and stained for expression of the injection marker (GFP) using an anti-GFP polyclonal antibody (MBL, 598), and for S-phase entry using an antiBrdU monoclonal antibody (Dako, M0744). Cells were subsequently scored for survival (GFP) and cell cycle progression (BrdU) . Approximately 1000 cells were injected per sample and 150 GFP-positive cells were counted per sample and scored for BrdU fluorescence. Reporter assays p21 CIP1 deletion constructs and p21 CIP1 mutation constructs were a kind gift from Dr Xiao-Fan Wang, Duke University (Datto et al., 1995) , Gal-p53AD, Gal-VP16, Bax gpGL3-Luc, and p21 CIP1gpGL3-Luc were a kind gift from Dr Neil Perkins, Dundee. CEFs were plated in 60 mm dishes at densities of 2.5 Â 10 5 cells/dish. Cells were transfected overnight with 5 mg plasmid DNA using the DOTAP method (Roche). Medium was changed and cells were harvested 48 h later. Cells were lysed and luciferase activity was measured using a luminometer. The luciferase activities were normalized to both protein concentration and transfection efficiency, and each experiment was performed at least three times. CAT assays were performed as described previously (Kilbey et al., 1996) .
Preparation of cell extracts and Western blotting
Whole-cell extracts were prepared from CEF cultures as previously described (Clark and Gillespie, 1997) to analyse Jun expression, and nuclear extracts were prepared to analyse p53 expression as described before . For chick p21 CIP1 expression, CEFs were lysed directly into SDS sample buffer (100 mm Tris-HCl pH6.8, 4% SDS, 0.2% bromophenol blue, 20% glycerol, 80 ml/ml b2-mercaptoethanol). Extracts were separated by SDS-polyacrylamide gel electrophoresis (PAGE) and analysed by Western blotting as described previously (Clark and Gillespie, 1997) . The antisera used for Western blotting were as follows: anti-p53 (Santa Cruz sc-99), anti-human p21 CIP1 (Santa Cruz sc-397), antiErk (Sigma M5670), and anti-Jun (Transduction Labs, J31920). An avian-specific p21 CIP1 polyclonal antiserum was generated by immunizing rabbits with a thrombin cleaved full-length chick GST-p21 CIP1 protein. The resulting polyclonal antiserum was used at a dilution of 1/5000 for Western blotting.
Kinase assays
For immunoprecipitation kinase assays, cell extracts were prepared in lysis buffer as described previously . Extracts were incubated with anti-cdk2 antibody (S. Cruz sc-163) for 3 h at 41C. Immune complexes were captured on sepharose beads coated with protein A and washed three times in lysis buffer. Captured complexes were subsequently washed twice in kinase buffer (50 mm HEPES pH7.5, 10 mm MgCl 2 , 10 mm MnCl 2 , and 1 mm dithiothreitol). Kinase reactions were performed in the presence of 20 mm ATP, 0.1 mm protein kinase A inhibitor, 10mCi [g 32 P]ATP, and 1 mg histone H1 as substrate. Assays were performed at 301C for 30 min, proteins were then denatured and resolved by SDS-polyacryamide gel analysis. Gels were dried and exposed to autoradiographic film at -701C. Quantitation of kinase activity was performed by laser densitometry of the autoradiograph.
Flow cytometry
For cell cycle analysis, CEFs were incubated with 25 mm BrdU for 1 h. Fixed cells were resuspended in PBS and stained as described previously (Clark and Gillespie, 1997) .
RNA extraction and Northern blotting
Total RNA was extracted from CEFs using RNAzol (Ambion) according to the manufacturer's instructions to examine p21 CIP1 expression. PolyA + RNA was prepared to analyse p53 expression using a polyATract mRNA Isolation Kit (Promega). Total RNA (30 mg) or 2-3 mg polyA + RNA was electrophoresed on a 1% formaldehyde/MOPS agarose gel and transferred to Hybond-N nylon membrane. RNA was crosslinked onto the membrane using a Stratagene UVcrosslinker. The membrane was hybridized overnight at 651C in NaPO 4 /SDS buffer containing a radiolabelled 1.3 kB avian p21 CIP1 cDNA, or a chick p53 cDNA fragment. The membrane was washed to remove nonspecific background and exposed to autoradiographic film. Northern blots were quantitated relative to GAPDH loading controls using laser densitometry of the autoradiograph.
p53 DNA binding analysis
Oligonucleotides containing both p53REs of the Mdm2 promoter, either wild type or mutated as described above (but lacking the TRE site), were concatamerized, biotinylated, and captured on streptavidin-coated magnetic beads (Promega). Whole-cell extracts prepared from UV-treated cells were incubated with the oligo-coated beads for 90 min at 41C. Beads were subsequently washed to remove unbound proteins, and captured proteins were eluted and analysed by Western blotting as described above.
